Welcome to Richmond Pharmacology
Our reputation has been gained through the successful conduct of over 250 Early Phase Studies since inception in 2001, ranging from testing Anaesthetic agents to Zinamide interaction studies. The specialist areas in which we have really excelled over many years are Adaptive, Thorough-QT, Japanese Bridging Studies and Patient Recruitment – evident in the numerous peer-reviewed papers we have published.
Welcome to Richmond Pharmacology
Our Business Ethos
Our business ethos is unique: Our revenues serve the National Health Service and St George’s University of London, fund basic research, support charities or otherwise are reinvested in the business. Our business is sustainable, adaptive to change and is led by the same specialists who founded the business more than ten years ago.
All our sponsors are preferred clients. Richmond Pharmacology’s interaction with its sponsors is personal and truly strategic, generating enhanced value for drug developers and investors.
Our work is closely supervised throughout by the same senior specialists sponsors meet during the first consultation or bid defence. Our services span strategic consultancy and concept development through to final reporting, utilising our many years of experience and leading to successful clinical trials with meaningful results.
Read More »
Our Specialist Services
Thorough QTc Study Services (TQT Studies)
All our Thorough QT Studies are in collaboration with Professor Camm, Head of Cardiac and Vascular Sciences, St George's University of London, a world renowned opinion leader in cardiological analysis. In-house expertise and experience makes Richmond Pharmacology the ideal partner for performing definitive QTc Study Solutions. Read more about our Thorough Qt Studies
We're the leading global provider of Japanese Bridging Studies and have succesfully completed in excess of 50 bridging studies in Japanese subjects since 2002, many of which have already been used in regulatory submissions in Japan.
Richmond Pharmacology is Europe's longest established specialist in Japanese bridging studies, our MHRA accredited facilities can accommodate every aspect of a study including, protocol writing and CRF Design, Ethics and Regulatory Approvals, Study Data Management and Statistical Analysis. Our unique approach to volunteer recruitment has ensured that we are able to recruit a variety of Japanese volunteer populations to meet our sponsors' time and cost requirements. Take a look at our Bridging Studies or see Early Phase Bridging Studies to view our latest publications and a case study on RPL’s experience in challenging bridging studies.
First In Man Studies
Uniquely based with 2 prominent NHS London hospitals and certified by the highest level of Regulatory Accreditation, Richmond Pharmacology are First Time Into Human specialists. RPL's extensive experience means they can offer a broad spectrum of first in man study services. Learn More about our First in Man Studies
Our in-house Volunteer and Patient Recruitment department is the largest of any early phase CRO in the UK. We have extensive experience in recruiting a multitude of volunteer panels. Learn more about our Patient Recruitment
Adaptive Study Design
Established as Europe's industry leaders and backed by the support of a highly experienced team of clinical pharmacologists, project managers, a world-class Scientific Advisory Board and a wide range of on-site therapeutically aligned experts, RPL is perfectly equipped for the conduct of complex studies requiring the application of the Adaptive Study Design model in, but not limited to; FTIH, TQT, Japanese and Bridging Studies.
Learn more about adaptive design for early phase clinical trials»
Cardiac Safety Studies
As the leading specialist in Cardiac Safety Study Solutions, we know how important the quality of ECG data, speed and regulatory compliance is to our sponsors. It’s no surprise that Richmond Pharmacology’s Cardiac Safety Studies are trusted worldwide.
Learn more about our Cardiac Safety Studies »
Early Phase Studies
Our reputation has been gained through the successful conduct of over 250 Early Phase Studies since 2001. Our experience spans simple BE studies to complex FTIH studies. Our hospital integrated Phase I unit provides an optimum safety environment for Early Phase Studies »
Our Featured Publications
Click here to view all of Richmond Pharmacology's Publications and Book Chapters